血浆高敏肌钙蛋白T预测1型糖尿病合并糖尿病肾病患者的终末期肾病及心血管和全因死亡
本研究纳入442例无糖尿病肾病和458例有糖尿病肾病的1型糖尿病患者,分析基线血浆高敏肌钙蛋白T(hsTnT)水平,随访至12年。结果发现hsTnT在糖尿病肾病患者中显著升高(中位数8.9 vs 3.1 ng/L),且是肾脏功能下降和心血管事件的独立预测因子,并改善死亡风险预测。
要点
- 糖尿病肾病患者hsTnT水平显著高于无肾病患者(中位数8.9 vs 3.1 ng/L)。
- hsTnT翻倍与随访期间肾小球滤过率(GFR)年下降2.9 ml/min/1.73 m²显著相关。
- hsTnT可改善1型糖尿病患者的死亡风险预测(AUC增加0.01,相对IDI提高15.7%)。
核心结论
- 在1型糖尿病合并糖尿病肾病患者中,较高的hsTnT是肾脏功能下降和心血管事件的独立预测因子。
研究设计与样本
- 回顾性队列研究,纳入442例无糖尿病肾病和458例有糖尿病肾病的1型糖尿病患者,随访至12年。
主要发现
- 糖尿病肾病患者hsTnT中位数8.9 ng/L,显著高于无肾病患者的3.1 ng/L。
- 在糖尿病肾病组,hsTnT翻倍与随访期间GFR年下降2.9 ml/min/1.73 m²显著相关(校正后)。
- 在糖尿病肾病患者中,hsTnT翻倍与全因死亡的未校正和校正风险比分别为1.64和1.32,均显著。
- 在全队列和糖尿病肾病组中,hsTnT翻倍与致死性和非致死性心血管事件的校正风险比分别为1.13和1.14,均显著。
- 将hsTnT加入传统风险因素后,死亡预测的ROC曲线下面积显著增加0.01,相对IDI在死亡、心血管事件和ESRD分别提高15.7%、6.3%和1.9%(均显著)。
临床怎么用
- 对于1型糖尿病合并糖尿病肾病患者,可考虑检测血浆hsTnT以辅助评估肾脏功能下降和心血管事件风险。
局限性
- 本研究为观察性队列研究,hsTnT对终末期肾病(ESRD)的预测在糖尿病肾病组中校正后不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-sensitivity troponin T (hsTnT) is a marker of cardiovascular disease (CVD) and in type 2 diabetes also a marker of renal events, but has not been evaluated in type 1 diabetics. We therefore reviewed a type 1 diabetes cohort of 442 without and 458 with diabetic nephropathy. Baseline samples were analyzed for hsTnT levels. Cox regression analyses assessed predictive value in relation to the development of end-stage renal disease (ESRD) in 99 patients, all-cause mortality in 178, and CVD events in 134 after up to 12 years of follow-up. To assess if hsTnT improved risk prediction beyond traditional clinical risk markers, we calculated c statistics and relative integrated discrimination improvement. HsTnT was significantly higher in patients with diabetic nephropathy compared to normoalbuminuria (median 8.9 vs 3.1 ng/L). For a doubling in hsTnT levels, and after adjustment for well-known risk factors, including NT-proBNP and hsCRP, the hazard ratio for ESRD at 1.26 was not significant in the diabetic nephropathy group, but there was a significant association with GFR decline after adjustment during follow-up (2.9 ml/min/1.73 m2 annual decline per doubling in hsTnT). The unadjusted and adjusted hazard ratios for mortality (1.64 and 1.32, respectively) were significant in patients with, but not for patients without, nephropathy. Adjusted hazard ratios for fatal and non-fatal CVD events were significant for the whole cohort (1.13), and those with nephropathy (1.14), but not significant for normoalbuminuria (1.06). Addition of hsTNT to traditional risk factors significantly increased the area under the curve by 0.01 in a receiver-operating characteristic curve for mortality. The relative integrated discrimination improvement was increased 15.7% for mortality, 6.3% for CVD, and 1.9% for ESRD (all significant). Thus, higher hsTnT is an independent predictor of renal decline and cardiovascular events in patients with type 1 diabetes and diabetic nephropathy.
引用
- Galsgaard J, Persson F, Hansen TW, et al. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. Kidney Int. 2017. PMID: 28712855. doi:10.1016/j.kint.2017.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。